Bone Biologics Confirms Nasdaq Listing for Common Stock & Warrants
Ticker: BBLGW · Form: 8-K · Filed: Jan 11, 2024 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | 8-K |
| Filed Date | Jan 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, regulatory-filing, listing-status
TL;DR
**BBLG just filed an 8-K confirming its Nasdaq listing for stock and warrants, no major news.**
AI Summary
Bone Biologics Corp. filed an 8-K on January 11, 2024, reporting an event that occurred on January 8, 2024. This filing primarily serves to update the company's registration information with the SEC, confirming its common stock (BBLG) and warrants (BBLGW) are registered on The Nasdaq Stock Market LLC. While no specific personnel changes or financial transactions are detailed, it matters to investors as it reaffirms the company's compliance and listing status, which is foundational for trading and market visibility.
Why It Matters
This filing confirms Bone Biologics Corp.'s continued compliance with SEC regulations and its listing on The Nasdaq Stock Market LLC, providing transparency and maintaining investor confidence in its trading status.
Risk Assessment
Risk Level: low — This filing is largely administrative, confirming existing listing information, and does not introduce new financial or operational risks.
Analyst Insight
A smart investor would note this filing as routine compliance, confirming the company's listing status, but would not expect any immediate market-moving impact from this specific 8-K. Further research into the company's financials and operational updates would be necessary for investment decisions.
Key Numbers
- $0.001 — Par Value Per Share (The stated par value for Bone Biologics Corp.'s common stock.)
Key Players & Entities
- Bone Biologics Corporation (company) — the registrant filing the 8-K
- The Nasdaq Stock Market LLC (company) — the exchange where BBLG common stock and warrants are registered
- $0.001 (dollar_amount) — par value per share of common stock
- BBLG (company) — trading symbol for common stock
- BBLGW (company) — trading symbol for warrants
FAQ
What is the purpose of this 8-K filing by Bone Biologics Corp.?
The 8-K filing by Bone Biologics Corp. on January 11, 2024, primarily serves to update and confirm its registration information with the SEC, specifically noting that its common stock (BBLG) and warrants (BBLGW) are registered on The Nasdaq Stock Market LLC, as per the 'Securities registered pursuant to section 12(b) of the Act' section.
What is the trading symbol for Bone Biologics Corp.'s common stock and warrants?
According to the filing, the trading symbol for Bone Biologics Corp.'s common stock is BBLG, and the trading symbol for its warrants to purchase common stock is BBLGW, both registered on The Nasdaq Stock Market LLC.
What is the par value per share for Bone Biologics Corp.'s common stock?
The filing states that the common stock has a par value of $0.001 per share.
When was the earliest event reported in this 8-K filing?
The 'Date of Report (Date of earliest event reported)' is listed as January 8, 2024.
What is the business address and phone number of Bone Biologics Corp. as listed in the filing?
The business address is 2 Burlington Woods Drive, Suite 100, Burlington, MA 01803, and the telephone number is (781) 552-4452.
Filing Stats: 712 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2024-01-11 08:15:18
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share BBLG The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- 0001493152-24-002010.txt ( ) — 288KB
- bblg-20240108.xsd (EX-101.SCH) — 4KB
- bblg-20240108_def.xml (EX-101.DEF) — 26KB
- bblg-20240108_lab.xml (EX-101.LAB) — 36KB
- bblg-20240108_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits There are filed as part of this report the exhibits listed on the accompanying Index to Exhibits, which information is incorporated herein by reference.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 11, 2024 BONE BIOLOGICS CORPORATION By: /s/ JEFFREY FRELICK Name: Jeffrey Frelick Title: Chief Executive Officer INDEX TO EXHIBITS Exhibit Number Description 99.1 Press Release of Bone Biologics Corporation, dated January 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)